Xenon Pharmaceuticals Inc. (XENE)

NGM – Цена в реальном времени. Валюта: USD

55.00

-0.78 (-1.40%)

При закрытии: May 12, 2026, 4:00 PM EDT

09.05.2026

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Pharmaceuticals NASDAQ: XENE said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first quarter.

08.05.2026

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.

08.05.2026

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

07.05.2026

Xenon Reports Q1 2026 Financial Results and Provides Business Update

VANCOUVER, British Columbia and BOSTON, MA, May 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today reported financial results for the first quarter ended March 31, 2026 and provided a business update.

07.05.2026

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.

01.05.2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 25,600 share options and 15,000 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of April 30, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

22.04.2026

Xenon's Phase 3 Supports A 'Buy' Despite Its Premium

Xenon Pharmaceuticals Inc.'s bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient population. Azetukalner's differentiated Kv7 mechanism, once-daily dosing, and no-titration profile may help its future adoption, especially for polytreated epilepsy patients. XENE plans its NDA submission in Q3 2026, which would be a key transition toward potential commercialization and revenues.

Видео

No Data

There is no data to display

Пресс-релизы

07.05.2026

Xenon Reports Q1 2026 Financial Results and Provides Business Update

07.05.2026

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.

01.05.2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19.04.2026

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Xenon is also presenting data at the AAN meeting that reinforce the significant opportunity for azetukalner in epilepsy, including 48-month data from the ongoing X-TOLE open-label extension (OLE) study, as well as real-world data reinforcing the potential value that no-titration options like azetukalner would bring to epilepsy management. Azetukalner (AZK) is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.

Xenon Pharmaceuticals Inc. (XENE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon's Phase 3 Supports A 'Buy' Despite Its Premium

Видео

No Data

Пресс-релизы

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon's Phase 3 Supports A 'Buy' Despite Its Premium

Видео

No Data

Пресс-релизы

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Search stocks

Xenon Pharmaceuticals Inc. (XENE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon's Phase 3 Supports A 'Buy' Despite Its Premium

Видео

No Data

Пресс-релизы

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon's Phase 3 Supports A 'Buy' Despite Its Premium

Видео

No Data

Пресс-релизы

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting